Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.

Shaan Dudani,Chun Loo Gan,Connor Wells,Ziad Bakouny,Nazli Dizman,Sumanta K. Pal,Lori Wood,Christian K. Kollmannsberger,Bernadett Szabados,Thomas Powles,Benoit Beuselinck,Frede Donskov,Aaron Richard Hansen,Georg A. Bjarnason,Christina M. Canil,Sandy Srinivas,Neeraj Agarwal,Elizabeth Chien Hern Liow,Toni K. Choueiri,Daniel Yick Chin Heng

Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.

2020

5063Background: In patients with mRCC, the International mRCC Database Consortium (IMDC) criteria have been validated as a prognostic tool in patients treated with targeted therapy in the 1-4L sett...

Keywords:

Internal medicine
first line
Oncology
Renal cell carcinoma
Medicine
second line
Pathology
Targeted therapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations